Corvus Pharmaceuticals, Inc. — Director's Dealing 2021

Sep 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2021-09-09

Reporting Person: CLARK IAN T (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-09	Stock Option (Right to Buy)	$2.60	A	15000	Acquired	2031-09-09	Common Stock (15000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date.